Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SGMO |
---|---|---|
09:32 ET | 89461 | 2.335 |
09:33 ET | 33310 | 2.33 |
09:35 ET | 68422 | 2.305 |
09:37 ET | 19647 | 2.31 |
09:39 ET | 18736 | 2.294 |
09:42 ET | 58592 | 2.2619 |
09:44 ET | 64633 | 2.2664 |
09:46 ET | 24975 | 2.24 |
09:48 ET | 35561 | 2.27 |
09:50 ET | 9525 | 2.2799 |
09:51 ET | 14179 | 2.285 |
09:53 ET | 20235 | 2.2818 |
09:55 ET | 5875 | 2.3 |
09:57 ET | 18836 | 2.282 |
10:00 ET | 5100 | 2.285 |
10:02 ET | 42325 | 2.27 |
10:04 ET | 10353 | 2.256 |
10:06 ET | 40421 | 2.25 |
10:08 ET | 68721 | 2.24 |
10:09 ET | 15249 | 2.24 |
10:11 ET | 5296 | 2.245 |
10:13 ET | 15805 | 2.255 |
10:15 ET | 10440 | 2.2408 |
10:18 ET | 32373 | 2.21 |
10:20 ET | 28186 | 2.21 |
10:22 ET | 45425 | 2.199 |
10:24 ET | 35139 | 2.19 |
10:26 ET | 46206 | 2.2 |
10:27 ET | 13985 | 2.18 |
10:29 ET | 42550 | 2.185 |
10:31 ET | 23478 | 2.1949 |
10:33 ET | 22946 | 2.19 |
10:36 ET | 15282 | 2.19 |
10:38 ET | 26030 | 2.185 |
10:40 ET | 9572 | 2.185 |
10:42 ET | 24993 | 2.2 |
10:44 ET | 78101 | 2.185 |
10:45 ET | 34798 | 2.175 |
10:47 ET | 139457 | 2.15 |
10:49 ET | 62493 | 2.15 |
10:51 ET | 50116 | 2.14 |
10:54 ET | 21460 | 2.17 |
10:56 ET | 6398 | 2.17 |
10:58 ET | 26802 | 2.19 |
11:00 ET | 24264 | 2.18 |
11:02 ET | 4950 | 2.175 |
11:03 ET | 12074 | 2.1805 |
11:05 ET | 16649 | 2.2 |
11:07 ET | 7995 | 2.205 |
11:09 ET | 2100 | 2.205 |
11:12 ET | 22604 | 2.19 |
11:14 ET | 30233 | 2.175 |
11:16 ET | 4523 | 2.175 |
11:18 ET | 16661 | 2.1639 |
11:20 ET | 22807 | 2.165 |
11:21 ET | 19436 | 2.165 |
11:23 ET | 2430 | 2.165 |
11:25 ET | 9322 | 2.1888 |
11:27 ET | 7307 | 2.19 |
11:30 ET | 8737 | 2.185 |
11:32 ET | 4958 | 2.185 |
11:34 ET | 18926 | 2.195 |
11:36 ET | 9735 | 2.195 |
11:38 ET | 10848 | 2.1998 |
11:39 ET | 13234 | 2.18 |
11:41 ET | 33038 | 2.1798 |
11:43 ET | 76664 | 2.16 |
11:45 ET | 8372 | 2.16 |
11:48 ET | 17608 | 2.19 |
11:50 ET | 2597 | 2.1899 |
11:52 ET | 2531 | 2.185 |
11:54 ET | 7082 | 2.18 |
11:56 ET | 3328 | 2.185 |
11:57 ET | 2866 | 2.18 |
11:59 ET | 4394 | 2.175 |
12:01 ET | 11735 | 2.19 |
12:03 ET | 2469 | 2.1892 |
12:06 ET | 27120 | 2.2 |
12:08 ET | 3958 | 2.195 |
12:10 ET | 6208 | 2.19 |
12:12 ET | 7325 | 2.19 |
12:14 ET | 1058 | 2.195 |
12:15 ET | 4697 | 2.19 |
12:17 ET | 2491 | 2.18 |
12:19 ET | 2605 | 2.18 |
12:21 ET | 87127 | 2.21 |
12:24 ET | 28824 | 2.2 |
12:26 ET | 27513 | 2.205 |
12:28 ET | 2968 | 2.2 |
12:30 ET | 14965 | 2.205 |
12:32 ET | 59446 | 2.21 |
12:33 ET | 9398 | 2.2087 |
12:35 ET | 1747 | 2.205 |
12:37 ET | 26111 | 2.205 |
12:39 ET | 1629 | 2.205 |
12:42 ET | 40274 | 2.23 |
12:44 ET | 21235 | 2.23 |
12:46 ET | 22240 | 2.245 |
12:48 ET | 15000 | 2.25 |
12:50 ET | 17353 | 2.25 |
12:51 ET | 90965 | 2.255 |
12:53 ET | 13755 | 2.255 |
12:55 ET | 35890 | 2.24 |
12:57 ET | 48847 | 2.26 |
01:00 ET | 173129 | 2.26 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Sangamo Therapeutics Inc | 479.9M | -3.2x | --- |
Arcturus Therapeutics Holdings Inc | 474.3M | -7.9x | --- |
Akebia Therapeutics Inc | 449.5M | -9.3x | --- |
Vanda Pharmaceuticals Inc | 302.6M | -18.2x | -37.98% |
Kamada Ltd | 334.0M | 19.0x | -22.48% |
Sutro Biopharma Inc | 221.8M | -1.6x | --- |
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $479.9M |
---|---|
Revenue (TTM) | $52.3M |
Shares Outstanding | 208.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.15 |
EPS | $-0.71 |
Book Value | $0.47 |
P/E Ratio | -3.2x |
Price/Sales (TTM) | 9.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -267.81% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.